CLEC7A and early-onset autosomal dominant Alzheimer disease: These findings provide a foundation for the development of Clec7a-targeted therapies aimed at slowing the progression of Alzheimer’s disease and other neurodegenerative disorders characterized by synaptic dysfunction.